Boston Scientific is reaping the rewards from the energised PFA market opportunity in atrial fibrillation treatment.

Magdalena aiming to submit Investigational New Drug (IND) application in 2025 to the FDA for a next-generation psychoactive prescription drug candidate for potential mental health indications such as ...

CHARLOTTE, N.C. - Dentsply Sirona Inc. (NASDAQ:XRAY), a global leader in dental products and technologies, has announced the ...

Target’s stock price plummeted 22% on Nov. 20, 2024, destroying nearly $16 billion in market cap in a single day after the ...

Following the president’s recent executive order dismantling diversity, equity, and inclusion policies, the main page for the ...

Target has been the center of endless backlash and boycotts due to its multiple controversial business moves. These moves ...

Senator Cory Booker and Representative Rosa DeLauro introduced a bill to provide FDA the authority to collect microbial ...

Greg Rodetis; Senior Vice President, Treasurer and Head of Investor Relations; Becton Dickinson and Co Thomas Polen; Chairman of the Board, President, Chief Executive Officer; Becton Dickinson and Co ...

February 6, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, today announced that the first subject has ...

The National Transportation Safety Board released findings from its investigation into the CTA Yellow Line crash that left 19 wounded in 2023.